TMED8

Across TCGA pan-cancer cohorts, TMED8 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TMED8 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMED8 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMED8 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where TMED8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.904	0.105	.008	25	view →
UCEC	DFS	Tertile	All	1.000	0.830	.002	12	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	9	view →
LUAD	OS	Median	III,IV	0.333	0.911	.017	7	view →
LSCC	DFS	Median	All	0.912	0.460	.007	7	view →
HNSC	DFS	Quartile	III,IV	0.990	0.687	.021	4	view →
GBM	OS	Median	All	0.787	0.924	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TMED8–CCRCC (DFS)

Open the CCRCC breakdown →